– USA, MA – Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the appointment of Dr. Zhen Su MD to its Board of Directors, effective August 31, 2023.
“Dr. Su is a physician‐scientist and pharmaceutical industry leader who brings tremendous experience guiding products through discovery, clinical development, approval, and global commercialization,. His expertise and counsel will be critical to us as we expand into different patient populations and potential new indications in oncology. We are delighted to welcome him to our team and look forward to the insight he will provide as part of our Board of Directors” said CEO, Dr. Richard Paulson.
About Dr. Zhen Su
Dr. Su is currently CEO and a member of the Board of Directors at Marengo Therapeutics, Inc., a company pioneering novel T-cell targeting therapeutics to fight cancer.
“I am pleased to join the Board of Karyopharm at this exciting time in the company’s next phase of growth,” said Dr. Zhen Su. “I look forward to actively engaging with my fellow Board members and the Karyopharm leadership team to advance its core programs and deliver for patients in need of new cancer treatment options.”
Prior to joining Marengo, Dr. Su served as SVP, Global Head of the Oncology Business Franchise, including US Head of the Oncology Business Unit, at Merck KGaA. Prior to that, he served as Chief Medical Officer at EMD Serono and headed leadership functions at Sanofi’s Oncology Division and GlaxoSmithKline. Before his industry career, Dr. Su served on the faculty of Duke University Medical School where he led early oncology clinical studies focusing on mRNA-based and cell-based immunotherapy and then at the University of Florida where he was the director of the Cell and Gene Therapy program.
He received his Doctor of Medicine from the Technical University of Dresden in Germany and his MBA from the University of Toronto in Canada.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company pioneering novel cancer therapies. Since its founding, Karyopharm has been an industry leader in oral Selective Inhibitor of Nuclear Export (SINE) compound technology, which was developed to address a fundamental mechanism of oncogenesis: nuclear export dysregulation. Karyopharm’s lead SINE compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications and has received regulatory approvals in various indications in a growing number of ex-U.S. territories and countries, including Europe and the United Kingdom (as NEXPOVIO) and China. Karyopharm has a focused pipeline targeting multiple high unmet-need cancer indications, including in multiple myeloma, endometrial cancer, myelodysplastic neoplasms, and myelofibrosis.
SOURCE: https://www.karyopharm.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.